Table 1 The characteristics of stage IB GAC patients before and after PSM

Year at diagnosis:

< 0.001

0.446

 2004–2007

700 (37.1%)

215 (30.4%)

485 (41.1%)

362 (33.6%)

173 (32.1%)

189 (35.1%)

 2008–2011

609 (32.2%)

217 (30.6%)

392 (33.2%)

354 (32.8%)

176 (32.7%)

178 (33.0%)

 2012–2015

580 (30.7%)

276 (39.0%)

304 (25.7%)

362 (33.6%)

190 (35.3%)

172 (31.9%)

 Age

68.4 (12.3)

62.4 (11.3)

72.0 (11.5)

< 0.001

64.9 (10.7)

64.9 (10.3)

65.0 (11.1)

0.822

Gender:

0.003

0.365

 Female

690 (36.5%)

228 (32.2%)

462 (39.1%)

357 (33.1%)

186 (34.5%)

171 (31.7%)

 Male

1199 (63.5%)

480 (67.8%)

719 (60.9%)

721 (66.9%)

353 (65.5%)

368 (68.3%)

Race:

0.091

0.897

 White

1245 (65.9%)

484 (68.4%)

761 (64.4%)

725 (67.3%)

361 (67.0%)

364 (67.5%)

 Non-White

644 (34.1%)

224 (31.6%)

420 (35.6%)

353 (32.7%)

178 (33.0%)

175 (32.5%)

Marital status:

0.001

0.795

 Married

1201 (63.6%)

483 (68.2%)

718 (60.8%)

727 (67.4%)

366 (67.9%)

361 (67.0%)

 Unmarried

688 (36.4%)

225 (31.8%)

463 (39.2%)

351 (32.6%)

173 (32.1%)

178 (33.0%)

Grade:

< 0.001

0.621

 I/II

846 (44.8%)

278 (39.3%)

568 (48.1%)

449 (41.7%)

220 (40.8%)

229 (42.5%)

 III/IV

1043 (55.2%)

430 (60.7%)

613 (51.9%)

629 (58.3%)

319 (59.2%)

310 (57.5%)

Pathology:

0.01

0.736

 Non-SRCC

1613 (85.4%)

585 (82.6%)

1028 (87.0%)

911 (84.5%)

458 (85.0%)

453 (84.0%)

 SRCC

276 (14.6%)

123 (17.4%)

153 (13.0%)

167 (15.5%)

81 (15.0%)

86 (16.0%)

Primary site:

< 0.001

0.888

 Cardia

540 (28.6%)

278 (39.3%)

262 (22.2%)

367 (34.0%)

183 (34.0%)

184 (34.1%)

 Distal site

603 (31.9%)

179 (25.3%)

424 (35.9%)

294 (27.3%)

152 (28.2%)

142 (26.3%)

 Middle site

547 (29.0%)

191 (27.0%)

356 (30.1%)

314 (29.1%)

155 (28.8%)

159 (29.5%)

 Overlapping/NOS

199 (10.5%)

60 (8.5%)

139 (11.8%)

103 (9.6%)

49 (9.1%)

54 (10.0%)

Tumor size:

< 0.001

0.782

 ≤ 2 cm

542 (28.7%)

216 (30.5%)

326 (27.6%)

319 (29.6%)

162 (30.1%)

157 (29.1%)

 ≤ 5 cm

908 (48.1%)

308 (43.5%)

600 (50.8%)

506 (46.9%)

247 (45.8%)

259 (48.1%)

 > 5 cm

296 (15.7%)

98 (13.8%)

198 (16.8%)

163 (15.1%)

81 (15.0%)

82 (15.2%)

 Unknown

143 (7.6%)

86 (12.1%)

57 (4.8%)

90 (8.3%)

49 (9.1%)

41 (7.6%)

RNE:

0.007

0.39

 ≥ 16

738 (39.1%)

305 (43.1%)

433 (36.7%)

471 (43.7%)

228 (42.3%)

243 (45.1%)

 1–15

1151 (60.9%)

403 (56.9%)

748 (63.3%)

607 (56.3%)

311 (57.7%)

296 (54.9%)

Stage:

< 0.001

0.849

 T1N1M0

579 (30.7%)

322 (45.5%)

257 (21.8%)

384 (35.6%)

194 (36.0%)

190 (35.3%)

 T2N0M0

1310 (69.3%)

386 (54.5%)

924 (78.2%)

694 (64.4%)

345 (64.0%)

349 (64.7%)